E0609 Betulin Derivatives, Betulinic Acid and Lupeol

Have a look at our PowerPoint Introduction and Brochure describing deliverables, differentiators and case studies. Eight case studies can also be reviewed.

The objective of this project was to determine the potential opportunities in betulin derivatives, with a particular focus on betulinic acid and lupeol. CPL would provides a ‘snapshot’ of the main characteristics of the industries and markets into which betulin derivatives are, or could potentially, be sold. In addition, CPL identifies opportunities, supply chain structure and potential partners in the most appropriate market sectors.

Following analysis of all the information about the market potential for betulin derivatives, betulinic acid and lupeol, CPL advises in respect of the likely size and scope of the opportunities. Identifying barriers to entry and success factors for supply of plant/tree-derived chemical bioactives into potential markets such as pharmaceuticals, fine chemicals, dietary supplements and cosmetics are determined. CPL advises on which opportunities are likely to have most potential and which partners would be likely to be most suitable to access those opportunities.

Click to see the contents of the study or look below for an outline.

Table of Contents

Objective

Background

Scope

Method

Principal Findings

  • Properties and Sources
  • Overview of Betulin/Betulin Derivative’s Markets
  • Research and Patents
  • Pharmaceuticals
  • Fine Chemicals
  • Dietary Supplements
  • Cosmetics

Conclusions

  • Overview of Betulin/Betulin Derivatives Markets
  • Fine Chemicals and Pharmaceuticals
  • Dietary Supplements
  • Cosmetics

Recommendations

  • Cosmetics
  • Pharmaceuticals & Fine Chemicals
  • Dietary supplements

Betulin and Derivatives

  • Terpenes Background
  • Lupeol
  • Betulin
  • Betulinic Acid
  • Isolation of Betulinic Acid
  • Synthesis of Betulinic Acid

Scientific Research

  • Betulin
    • Actinic keratosis
    • Antiphlogistic Activity
    • Herpes
  • Betulinic Acid
    • Actinic keratosis
    • Antiphlogistic Activity
    • Cancer
    • HIV
    • Other
  • Lupeol
    • Antiphlogistic Activity
    • Other

Patents

  • Manufacturing of Betulin
  • Applications of Betulin
  • Manufacturing of Betulinic Acid
  • Applications of Betulinic Acid
  • Manufacturing of Lupeol
  • Applications of Lupeol

Potential of Betulin and Derivatives in Pharmaceuticals

  • Overview
  • Opportunities
  • Contact Overview
  • Potential Partners
  • Companies with Pharmaceutical Research activities relating to Betulin, Betulinic acid Lupeol
  • Additional Material
  • HIV
    • Markets & Trends
    • Products
    • Statistics
  • Cancer
    • Markets and Trends
    • Products
    • Statistics
  • Malignant Melanoma
    • Markets and Trends
    • Products
    • Statistics
  • Actinic keratosis
    • Market and Trends
    • Products
    • Statistics
  • Herpes
    • Market and Trends
    • Products
    • Statistics

Potential of Betulin and Derivatives in Cosmetics/Cosmeceuticals

  • The Characteristics of the Cosmetics/Personal Care and Supply Industry
  • Opportunities in Cosmetics/Cosmeceuticals
  • Betulin and Derivatives as Cosmeceuticals
  • Contact Overview
  • Potential Partners
  • Companies in the Bioactive Supply Business (examples)
  • Companies with Consumer Products Containing Betulin, Betulinic acid or Lupeol
  • Formulators using Betulin, Betulinic acid or Lupeol as an Ingredient
  • Companies with Cosmetic Research Activities relating to Betulin, Betulinic acid or Lupeol

Potential of Betulin and Derivatives in Dietary Supplements

  • Opportunities
  • Contact Overview
  • Potential Partners
  • Companies with Products Containing Betulin, Betulinic acid or Lupeol

Potential of Betulin and Derivatives in Fine Chemicals

  • Opportunities
  • Contact Overview
  • Potential Partners
  • Companies currently supplying triterpene derivatives as fine chemicals

Overview of The Current Market for Triterpene Derivatives

  • Market
  • Current Players, Products and Prices
    • Manufacturers
    • Processors and Traders

Overview Of The Global Pharmaceutical Industry

  • Market
  • Market Trends
  • The Drug Development Process
    • Cost of developing a new medicine
    • Drug development and the conduct of medical research
    • Clinical trials
    • Success rates in Drug Development
    • The promotion of drugs
    • Market Penetration for New Drugs
    • Historical Data
  • Intellectual Property Protection
    • Procedures for Drug Approval
  • Player

The Pharmaceutical Industry by Region

  • The US Pharmaceutical Industry
  • The European Pharmaceutical Industry
  • US vs. Europe – Competitive Comparison
  • The Pharmaceutical Industry in the ROW

Overview Of Global Fine Chemicals Industry

  • Definitions
    • Performance and Speciality chemicals
    • Pharmaceutical Fine Chemicals
  • Market Size
  • Market Structure
    • North America
    • Europe
    • Asia
  • Market Trends
    • Market drivers
    • Market Barriers
  • Main Players

Overview Of Global Cosmetics Industry

Markets And Trends

10 Main Players

Regulatory

  • Regulation of Cosmetics in the EU
  • Regulation of Cosmetics in the USA
  • Regulation of Cosmetics in Canada
  • Regulation of Cosmetics in Japan

Overview Of Global Dietary Supplement Industry

  • Dietary Supplements
    • Definitions
    • Product Categories
    • Distribution Channels
    • Market Structure
    • Product and Brand Differentiation
  • Markets and Trends
    • Market Drivers
    • Success Factors
    • Barriers to Entry
  • Main Players
    • US
    • EU
  • Regulatory
    • US
    • EU

News

39 Contact Reports 451

  • 9 Academia 451 27 Chemical Manufacturers, Processors and Traders 457 10 Pharmaceutical Industry 519 19 Cosmetic Industry 528 13 Fine Chemical Industry 550 20
  • Dietary Supplement Industry 561

Tables

  • Table 1 Overview of the potential market for triterpene derivatives in pharmaceuticals
  • Table 2 Overview of potential partners in the pharmaceutical industry
  • Table 3 Sales of anti-HIV drugs, 2005
  • Table 4 Costs involved in HIV treatment, 2006
  • Table 5 Market size and estimated growth for oncology treatments, 2004-2010
  • Table 6 Sales of top 20 cancer treatments in major pharmaceutical markets, 2004
  • Table 7 Cancer incidence rates in the US by race and sex, 2006
  • Table 8 Estimates of cancer prevalence in 17 (*) European countries, 2002
  • Table 9 The 10 cancers with the highest mortality in 38 (*) European countries,1998
  • Table 10 The early stages of malignant melanoma
  • Table 11 The latter stages of malignant melanoma
  • Table 12 Global Melanoma Statistics Overview (Females)
  • Table 13 Global Melanoma Statistics Overview (Males)
  • Table 14 Global Incidence and Prevalence of malignant melanoma, 2002
  • Table 15 Malignant melanoma prevalence in the United States (1st Jan 2002)
  • Table 16 Numbers and rates of malignant Melanoma in the UK, 2002
  • Table 17 Incidence of Actinic keratosis
  • Table 18 Sales of Drugs against Herpes Viruses, 2000-2005
  • Table 19 Sales of labial herpes drugs, $m (2004-2005)
  • Table 20 Estimated price and cost for prescribable herpes treatments
  • Table 21 Price comparison of generic acyclovir drugs
  • Table 22 Herpes diagnoses at GUM clinics in the UK, 1995-2004
  • Table 23 Interest from potential partners in the cosmetics industry.
  • Table 24 Main current uses of triterpene extracts in dietary supplements
  • Table 25 Interest from potential partners in the dietary supplement industry.
  • Table 26 Interest from potential partners in the fine chemical industry.
  • Table 27 Manufacturers and processors of betulin, listed by price of product
  • Table 28 Manufacturers and processors of betulinic acid, listed by price of product
  • Table 29 Global manufacturers and processors of lupeol, listed by price of product
  • Table 30 Overview of patents filed by NaturNorth
  • Table 31 Global Pharmaceutical Market, $b (2000-2010)
  • Table 32 Size of the Pharmaceutical Market, 1985-1999, $b
  • Table 33 Largest Pharmaceutical Markets (1989-1999), $m
  • Table 34 Market Consolidation in the Global Pharmaceutical Industry
  • Table 35 The EU Pharmaceutical Industry in figures (2004)
  • Table 36 Research and Development in the EU Pharmaceutical Industry (2004)
  • Table 37 The Pharmaceutical Market in Europe, €b (2003)
  • Table 38 The German Pharmaceutical Basic Substances Market, €b (2004)
  • Table 39 Market Size of the Italian Pharmaceutical Market $m (2004)
  • Table 40 Italian Import and Export of Pharmaceuticals (2004)
  • Table 41 Market Size for the Brazilian pharmaceutical industry, $m (2004-2006)
  • Table 42 Market Size for the Chilean Pharmaceutical industry, $m (2003-2005)
  • Table 43 Definitions of terms used in the fine chemical industry
  • Table 44 Types and numbers of Fine Chemical companies
  • Table 45 Customers of the Fine Chemicals industry
  • Table 46 Global Value of Amino Acids in Synthesis Applications through 2009 ($m)
  • Table 47 Recent Activity in the Fine Chemicals industry
  • Table 48 Top 10 companies in the Fine Chemicals industry
  • Table 49 Cosmetic product category with greatest growth by region, 2004-2005
  • Table 50 The global top 10 players in the cosmetics and toiletries market, 2006
  • Table 51 List of Dietary Supplement product Categories
  • Table 52 The Most Common Dietary Supplements and its Benefits
  • Table 53 Market Concentration in the Dietary Supplement Industry in the US
  • Table 54 US dietary supplement market by manufacturer / marketer
  • Table 55 Estimated Dietary Supplement market size by product category in US, 2001

Figures

  • Figure 1 Chemical structure of isoprene
  • Figure 2 Chemical structure of squalene
  • Figure 3 Chemical structure of lupeol
  • Figure 4 Chemical structure of betulin
  • Figure 5 Chemical structure of betulinic acid
  • Figure 6 A two-step synthetic scheme for the preparation of betulinic acid from betulin
  • Figure 7 A five-step synthetic scheme for the production of betulinic acid from betulin
  • Figure 8 Anti cancer activity of betulinic acid and several of its derivatives.
  • Figure 9 Anti-HIV-1activity of betulinic acid and several of its derivatives
  • Figure 10 The Betulin derivative, IC9564, an anti-entry active HIV drug
  • Figure 11 A bi-functional drug with clinical potential
  • Figure 12 Survival curve for Melanoma stage IV
  • Figure 13 World age-standardised incidence rates of malignant melanoma, 2002
  • Figure 14 Percentage distribution of malignant melanoma on parts of your body
  • Figure 15 European age-standardised incidence rates of malignant melanoma, 2002
  • Figure 16 Age specific incidence rates for malign melanoma in the UK, 2002
  • Figure 17 Incidence and mortality of malignant melanoma in Great Britain, 1975-2003
  • Figure 18 Incidence rates of malignant melanoma for men in Great Britain, 1975-2002
  • Figure 19 Incidence rates of malignant melanoma for women in Great Britain, 1975-2002
  • Figure 20 Genital herpes – Initial visits to physicians’ offices: United States, 1966-2004
  • Figure 21 Cost of developing a new medicine (1979 – 2003)
  • Figure 22 Development of a drug from target identification to post-launch product review
  • Figure 23 New Molecular Entities approved in the US, 1996–2003
  • Figure 24 Success rates in drug development
  • Figure 25 Percentage market share for products launched in the last five years (2003)
  • Figure 26 Pharmaceutical Industry Expenditure in R&D in Europe (2002)
  • Figure 27 Split of European Pharmaceutical Market (2004)
  • Figure 28 Funding of health-related R&D in the UK
  • Figure 29 Comparison of share of global pharmaceutical R&D investment
  • Figure 30 Fine Chemicals Breakdown by Target Sectors
  • Figure 31 Breakdown of Fine Chemicals by Production Type
  • Figure 32 Global sales of cosmetics and toiletries (1999-2005)
  • Figure 33 Cosmetics and toiletries market performance by region, 2006
  • Figure 34 Sales per product category in the cosmetic industry, 2005
  • Figure 35 Global growth per product category in the cosmetic industry, 2004-2005
  • Figure 36 US Dietary Supplement Sales by Market Channel
  • Figure 37 US Dietary Supplement Market by Category

CPL Gallery

Previous Image
Next Image